analysi sales/earn
one-year price volum histori
continu expect multipl catalyst
yesterday after-market close harpoon press-releas financi
result corpor updat compani end quarter
cash cash-equival market secur regard corpor
updat appear minim impact pandem
anticip mileston review note begin
expect clinic data encourag data updat
could valid platform look forward addit
value-driv mileston expect
updat interim result phase dose escal studi
present may et
select t-cell engag tritac bind domain albumin
bind domain tumor antigen bind domain recogn psma
phase studi evalu safeti toler pk weekli iv
dose patient advanc prostat cancer refractori androgen
therapi dose escal still on-going full efficaci potenti
may discern studi approach clinic meaning
dose therefor hope see posit signal includ increas target
engag long circul time limit well earli evid
clinic activ inclus time studi result studi
expect determin dose expans cohort begin
enrol note updat result provid
valid platform harpoon plan host virtual investor event
may pm et review data provid pipelin updat
interim poc data readout phase studi also
still expect similar t-cell engag
tritac recogn mesothelin msln due increas product
surfac msln tumor cell across variou solid tumor includ ovarian
cancer repres larg market opportun harpoon phase
studi evalu safeti toler pk patient
advanc msln cancer resist avail therapi
time readout remain track
harpoon recent initi phase studi plan
also initi phase studi harpoon recent
announc start phase studi bcma tritac
accompani mileston payment partner abbvi
abbv-nc detail phase studi tritac also
expect begin make catalyst-rich year harpoon
import disclosur regul ac certif locat page report
price target weight use probabl success
weight use probabl success net cash base dcf-npv-sop
analysi use discount rate growth rate factor could imped achiev
target price includ limit failur gain regulatori approv
smaller project commerci revenu drug expect late line product
clinic develop risk tritac space slowli becom competit potenti
enrol occur slower pace project current clinic program limit clinic
data present degrad date chang efficaci safeti profil could occur would
therefor materi stock
regulatori risk guarante fda approv either harpoon clinic program
pipelin asset therefor drug candid valuat multipl reason
could fail receiv fda approv also possibl even approv approv timelin
could vari project
commerci risk major development-stag biotechnolog compani commerci
prospect pipelin candid essenti present valuat current multipl competitor
market penetr estim could vari project also possibl
market may abl toler price point use market model therefor
revenu could come lower estim
financ risk major development-stag biotechnolog compani abil maintain
suffici fund critic progress pipelin commerci candid compani
experi problem rais suffici capit progress develop program could significantli
imped lead delay develop timelin well neg effect investor confid
could neg impact share price
harpoon clinic stage biotechnolog compani focus develop novel t-cell engag use
tri-specif t-cell activ construct tritac platform design har bodi natur protein
dispos system select engag kill host tumor variou cancer compani current
partnership werewolf therapeut provid substanti valid
platform harpoon also two lead clinic program next clinic program
compani strateg chosen use well valid target earli program therefor
posit expect clinic date readout expect
page
incom statement million
collabor licens revenu
revenu
research develop
gener administr
compani sec file roth capit partner research
page
ulat analyst certif ac research analyst primarili respons content report certifi
follow ac herebi certifi view express report accur reflect person view
subject compani compani secur also certifi part compens
directli indirectli relat specif recommend view express report
